Tc-RGD-βAla-(Arg 11 )CCMSH displayed higher melanoma uptake than 99m Tc-RGDAhx-(Arg 11 )CCMSH at 0.5, 2, 4, and 24 h post-injection. Enhanced tumor to kidney uptake ratio of 99m Tc-RGDβAla-(Arg 11 )CCMSH warranted the further evaluation of 188 Re-labeled RGD-βAla-(Arg 11 )CCMSH as a novel MC1 receptor-targeting therapeutic peptide for melanoma treatment in the future.
Introduction
G protein-coupled melanocortin-1 (MC1) receptors are over-expressed in human and murine melanoma cells (Chen et al. 2000; Guo et al. 2009a, b, c; Miao et al. 2003; Siegrist et al. 1989; Tatro et al. 1987; Yang et al. 2010a, b) , making the MC1 receptor a distinct molecular target.
Abstract
The purpose of this study was to examine whether the replacement of the positively-charged Lys or Arg linker with a neutral linker could reduce the renal uptake of Arg-Gly-Asp (RGD)-conjugated alpha-melanocyte stimulating hormone (α-MSH) hybrid peptide. The RGD motif {cyclic(Arg-Gly-Asp-DTyr-Asp)} was coupled to [Cys 3, 4, 10 , D-Phe 7 , Arg 11 ]α-MSH 3-13 {(Arg 11 ) CCMSH} through the neutral βAla or Ahx {aminohexa-noic acid} linker (replacing the Lys or Arg linker) to generate novel RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH hybrid peptides. The receptor-binding affinity and cytotoxicity of RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH were determined in B16/ F1 melanoma cells. The melanoma targeting and imaging properties of 99m Tc-RGD-βAla-(Arg 11 )CCMSH and 1 3
Targeting the MC1 receptors can differentiate melanoma cells from normal cells due to the higher levels of the MC1 receptors on melanoma cells. Thus, both linear and cyclic alpha-melanocyte-stimulating hormone (α-MSH) peptide radiopharmaceuticals have been reported to target the MC1 receptors for melanoma detection and treatment (Chen et al. 2001; Cheng et al. 2002 Cheng et al. , 2007 Froidevaux et al. 2002 Froidevaux et al. , 2004 Froidevaux et al. , 2005 Guo et al. 2009a Guo et al. , b, c, 2010 Miao et al. 2002 Miao et al. , 2005a Miao et al. , b, 2007 Miao et al. , 2008 Wei et al. 2007) . Recently, we have reported a novel class of Arg-Gly-Asp-conjugated α-MSH hybrid peptides targeting the MC1 receptors for potential melanoma imaging and therapy (Yang et al. 2009 (Yang et al. , 2010a . The RGD motif {cyclic(Arg-Gly-Asp-DTyr-Asp)} was used as an apoptosis inducer and was conjugated to the [Cys 3, 4, 10 , D-Phe 7 , Arg 11 ]α-MSH 3-13 {(Arg 11 )CCMSH} peptide through a Lys linker to yield RGD-Lys-(Arg 11 ) CCMSH hybrid peptide (Yang et al. 2009 ). RGD-Lys-(Arg 11 )CCMSH showed remarkable clonogenic cytotoxic effect in B16/F1 melanoma cells. Three-hour incubation with 0.1 µM of RGD-Lys-(Arg 11 )CCMSH decreased 65 % of the clonogenic survival of B16/F1 cells as compared to the untreated control cells six days post treatment. Meanwhile, 99m Tc-RGD-Lys-(Arg 11 )CCMSH displayed high B16/F1 melanoma uptake of 14.83 ± 2.94 % ID/g at 2 h post-injection (Yang et al. 2009 ). However, relatively high non-specific renal uptake of 99m Tc-RGD-Lys-(Arg 11 ) CCMSH (67.12 ± 8.79 % ID/g at 2 h post-injection) needed to be reduced to facilitate further evaluation of the α-MSH hybrid peptide for melanoma therapy in melanoma-bearing mice (Yang et al. 2009 ).
Recently, we found that the substitution of the Lys linker with the Arg linker dramatically improved the melanoma uptake by 44 % and reduced the renal uptake by 36 % at 2 h post-injection (Yang et al. 2010b ). RGD-Arg-(Arg 11 ) CCMSH displayed similar remarkable clonogenic cytotoxic effect as RGD-Lys-(Arg 11 )CCMSH in B16/F1 melanoma cells (Yang et al. 2010b ). Importantly, co-injection of 15 mg of l-lysine substantially decreased the renal uptake of 99m Tc-RGD-Lys-(Arg 11 )CCMSH by 52 % and the renal uptake of 99m Tc-RGD-Arg-(Arg 11 )CCMSH by 28 % at 2 h post-injection, indicating that the overall positive charges of 99m Tc-RGD-Lys-(Arg 11 )CCMSH and 99m Tc-RGD-Arg-(Arg 11 )CCMSH contributed to their non-specific renal uptake (Yang et al. 2010b) . Therefore, we hypothesized that further reduction of the overall positive charge of the 99m Tclabeled RGD-conjugated α-MSH hybrid peptide would further decrease its non-specific renal uptake. To examine our hypothesis, we synthesized two novel RGD-conjugated α-MSH hybrid peptides with less positive charges in this study. The RGD motif was coupled to the (Arg 11 )CCMSH peptide through the neutral βAla or Ahx hydrocarbon linker to generate new RGD-βAla-(Arg 11 )CCMSH and RGDAhx-(Arg 11 )CCMSH hybrid peptides. The neutral βAla − was purchased from Cardinal Health (Albuquerque, NM) for peptide radiolabeling. Cyclo(Arg-Gly-Asp-DPhe-Val) {RGD} peptide was purchased from Enzo Life Sciences (Plymouth Meeting, PA) for peptide blocking studies. All other chemicals used in this study were purchased from Thermo Fischer Scientific (Waltham, MA) and used without further purification. B16/F1 murine melanoma cells were obtained from American Type Culture Collection (Manassas, VA).
Peptide synthesis
New RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx- (Arg   11   ) CCMSH peptides were synthesized on Sieber amide resin using fluorenylmethyloxycarbonyl (Fmoc) chemistry by an Advanced ChemTech multiple-peptide synthesizer (Louisville, KY) according to our published procedure (Yang et al. 2009 ) with modifications. Briefly, 70 µmol of Sieber amide resin and 210 µmol of Fmoc-protected amino acids were used for the synthesis. Fmoc-βAla and Fmoc-Ahx were used to generate the βAla and Ahx linkers in the hybrid peptides, respectively. The intermediate scaffolds of
were synthesized on H 2 N-Sieber amide resin by an Advanced ChemTech multiple-peptide synthesizer (Louisville, KY). The protecting groups of 2-phenylisopropyl were removed and the peptides were cleaved from the resin treating with a mixture of 2.5 % of trifluoroacetic acid (TFA) and 5 % of triisopropylsilane. After the precipitation with ice-cold ether and characterization by liquid chromatography-mass spectroscopy (LC-MS), the protected peptides were dissolved in H 2 O/CH 3 CN (50:50) and lyophilized to remove the reagents such as TFA and triisopropylsilane. The protected peptides were further cyclized by coupling the carboxylic group from the Asp with the alpha-amino group from the Arg at the N-terminus. The cyclization reaction was achieved by overnight reaction in dimethylformamide (DMF) using benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium-hexafluorophosphate (PyBOP) as a coupling agent in the presence of N,N-diisopropylethylamine (DIEA). After characterization by LC-MS, the cyclized protected peptides were dissolved in H 2 O/CH 3 CN (50:50) and lyophilized to remove the reagents. The protecting groups were totally removed by treating with a mixture of trifluoroacetic acid (TFA), thioanisole, phenol, water, ethanedithiol, and triisopropylsilane (87.5:2.5:2.5:2.5:2.5:2.5) for 2 h at room temperature (25 °C). The peptides were precipitated and washed with ice-cold ether for four times, purified by reverse phase-high performance liquid chromatography (RP-HPLC) and characterized by LC-MS. The B16/F1 cells were seeded in 96-well plates (150 cells/ well) and incubated in a CO 2 incubator overnight. After being washed once with the culture medium (RPMI 1640 medium), the cells were incubated at 37 °C for 3 h in the presence of 0.1 μM of RGD-βAla-(Arg 11 )CCMSH, RGDAhx-(Arg 11 )CCMSH, (Arg 11 )CCMSH or RGD in 0.1 mL of the binding medium, respectively. The control cells were only incubated in the culture medium. After the incubation, the binding medium was aspirated. The cells were washed with culture medium once and returned to the CO 2 incubator to form colonies over 5 days in the culture medium. The culture medium was changed every other day. After 5 days, the culture medium was aspirated and the cells were incubated with 0.1 mL of 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) solution (0.5 mg/mL in PBS, pH 7.4) at 37 °C for 3 h until intracellular punctate purple precipitate (formazan) were observed. The formazan crystals yielded were dissolved in 0.1 mL of 0.1 N acidic anhydrous isopropanol. Spectrophotometric absorbance was measured at the wavelengths of 570 nm and 630 nm (as a control) using an microplate reader (SpectraMax 340, Molecule Devices), respectively. The absorbance of cells was calculated by substracting the value at 630 nm from the value at 570 nm. The percentage of survived cells was calculated as percentage survival = (absorbance of treated cells/absorbance of control cells) × 100 %.
Peptide radiolabelling
The RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 ) CCMSH peptides were radiolabeled with 99m Tc via a glucoheptonate transchelation reaction according to our published procedure (Yang et al. 2009 Tc-RGD-Ahx-(Arg 11 )CCMSH. For stability, biodistribution and imaging studies, each radiolabeled peptide was purified to single species by Waters RP-HPLC (Milford, MA) on a Grace Vydac C-18 reverse-phase analytical column (Deerfield, IL) using a 20-min gradient of 18-28 % acetonitrile in 20 mM HCl aqueous solution at a 1 mL/min flow rate. The stability of Tc-RGD-Ahx-(Arg 11 )CCMSH via the tail vein. Groups of 5 mice were sacrificed at 0.5, 2, 4, and 24 h post-injection, and tumors and organs of interest were harvested, weighed and counted in a gamma counter. Blood values were taken as 6.5 % of the whole-body weight. The specificity of the tumor uptake was determined by co-injecting Tc-RGD-Ahx-(Arg 11 )CCMSH with 10 μg (6.1 nmol) of unlabeled NDP-MSH or 3.5 μg (6.1 nmol) of RGD peptide at 2 h post-injection.
To determine the melanoma imaging properties, approximately 6.1 MBq of 99m Tc-RGD-βAla-(Arg 11 )CCMSH or 99m
Tc-RGD-Ahx-(Arg 11 )CCMSH was injected into B16/ F1 melanoma-bearing C57 mice via the tail vein, respectively. The mice were anesthetized with 1.5 % isoflurane for small animal SPECT/CT (Nano-SPECT/CT ® , Bioscan, Washington DC) imaging 2 h post-injection. The 9-min CT imaging was immediately followed by the SPECT imaging of whole-body. The SPECT scans of 24 projections were acquired. Reconstructed data from SPECT and CT were visualized and co-registered using InVivoScope (Bioscan, Washington DC).
Effect of co-injection of l-lysine on renal uptake
In attempt to further understand the roles of βAla and Ahx linkers in the renal uptake, the effect of l-lysine coinjection on the renal uptake of 99m Tc-RGD-βAla-(Arg 11 ) CCMSH and 99m Tc-RGD-Ahx-(Arg 11 )CCMSH was examined in B16/F1 melanoma-bearing C57 mice. Two groups of 5 mice were injected with an aqueous mixture of 0.037 MBq of 99m Tc-RGD-βAla-(Arg 11 )CCMSH and 15 mg of l-lysine or an aqueous mixture of 0.037 MBq of 99m Tc-RGD-Ahx-(Arg 11 )CCMSH and 15 mg of l-lysine, respectively. The mice were sacrificed at 2 h post-injection, and tumors and kidneys were harvested, weighed and counted in a gamma counter.
Statistical analysis
Statistical analysis was performed using the Student's t test for unpaired data to determine the significance of differences in tumor and kidney in biodistribution and coinjection of l-lysine studies, as well as the significance of differences in untreated control and treatment groups in cytotoxicity studies described above. Differences at the 95 % confidence level (p < 0.05) were considered significant.
Results
New RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 ) CCMSH were synthesized using Fmoc chemistry and purified by RP-HPLC. Figure 1 illustrates the structures of RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH. The structures of RGD-Lys-(Arg 11 ) CCMSH and RGD-Arg-(Arg 11 )CCMSH were cited for comparison. The peptide identities were confirmed by electrospray ionization mass spectrometry. The purities CCMSH were cited from the references (Yang et al. 2009 (Yang et al. , 2010b for comparison of RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 ) CCMSH were 96.5 and 97.2 %, respectively. The molecular weights of RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH are presented in Table 1 . The measured molecular weights of RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH were 2093.6 and 2136.1, respectively. The IC 50 values of RGD-βAla-(Arg 11 ) CCMSH and RGD-Ahx-(Arg 11 )CCMSH for MC1 receptor were 0.8 ± 0.05 and 1.3 ± 0.1 nM in B16/F1 melanoma cells (Table 1) .
The cytotoxic effects of RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH hybrid peptides were examined in B16/F1 melanoma cells. The results are presented in Fig. 2 . The survival percentages of the peptide-treated groups were normalized taking the survival percentage of untreated group (in culture medium) as 100 %. Both RGDβAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH exhibited remarkable cytotoxic effects in B16/F1 melanoma cells. Tables 2 and 3. 99m Tc-RGD-βAla-(Arg 11 )CCMSH exhibited rapid and high tumor uptake in melanoma-bearing mice. The tumor uptake value was 14.37 ± 1.75 % ID/g at 0.5 h post-injection. The tumor uptake value of Tc-RGD-βAla-(Arg 11 ) CCMSH with 3.5 µg (6.1 nmol) of RGD decreased 6 % of the tumor uptake (p > 0.05). Whole-body clearance of 99m Tc-RGD-βAla-(Arg 11 )CCMSH was rapid, with approximately 80 % of the injected radioactivity cleared through the urinary system by 2 h post-injection (Table 2) . Normal organ uptake of 99m Tc-RGD-βAla-(Arg 11 )CCMSH was generally low (<1.7 % ID/g) except for the kidneys after 2 h post-injection. High tumor/blood and tumor/muscle uptake ratios were demonstrated as early as 2 h postinjection ( Table 2 ). The renal uptake of 99m Tc-RGD-βAla-(Arg 11 )CCMSH reached its peak value of 25.64 ± 3.22 % ID/g at 0.5 h post-injection, and gradually decreased to 8.89 ± 0.84 % ID/g at 24 h post-injection.
99m Tc-RGD-Ahx-(Arg 11 )CCMSH exhibited similar biodistribution pattern as 99m Tc-RGD-βAla-(Arg 11 )CCMSH. Specifically, 99m Tc-RGD-Ahx-(Arg 11 )CCMSH displayed )CCMSH were cited from references (Yang et al. 2009 (Yang et al. , 2010b Tc-RGD-Ahx-(Arg 11 )CCMSH was 9.92 ± 1.49 % ID/g at 0.5 h post-injection. Tc-RGD-Ahx-(Arg 11 )CCMSH reached its peak tumor uptake value of 11.85 ± 1.95 % ID/g at 2 h post-injection. The tumor uptake value of 99m Tc-RGD-Ahx-(Arg 11 )CCMSH was 9.83 ± 1.03 % ID/g at 4 h post-injection, and gradually decreased to 5.51 ± 0.59 % ID/g at 24 h post-injection. Eighty-three percent of the tumor uptake of 99m Tc-RGD-Ahx-(Arg 11 ) CCMSH was blocked with 10 µg (6.1 nmol) of non-radiolabeled NDP-MSH at 2 h post-injection (p < 0.05), demonstrating that the tumor uptake was specific and MC1 receptor-mediated. Co-injection of Tc-RGD-Ahx-(Arg 11 )CCMSH was rapid, with approximately 76 % of the injected radioactivity cleared through the urinary system by 2 h post-injection (Table 3) . Normal organ uptake of 99m Tc-RGD-Ahx-(Arg 11 )CCMSH was generally low (<2.2 % ID/g) except for the kidneys after 2 h post-injection. High tumor/blood and tumor/muscle uptake ratios were demonstrated as early as 2 h postinjection (Table 3 ). The renal uptake of 99m Tc-RGD-Ahx-(Arg 11 )CCMSH reached its peak value of 24.03 ± 1.63 % ID/g at 0.5 h post-injection, and gradually decreased to 7.82 ± 1.66 % ID/g at 24 h post-injection.
The tumor to kidney uptake ratios of 99m Tc-RGD-βAla-(Arg 11 )CCMSH and 99m Tc-RGD-Ahx-(Arg 11 )CCMSH are summarized and compared with 99m Tc-RGD-Lys-(Arg 11 ) CCMSH and 99m Tc-RGD-Arg-(Arg 11 )CCMSH in Fig. 3 . 99m Tc-RGD-Ahx-(Arg 11 )CCMSH showed higher tumor to kidney uptake ratios than 99m Tc-RGD-Lys-(Arg 11 ) CCMSH and 99m Tc-RGD-Arg-(Arg 11 )CCMSH at 0.5, 2, 4, and 24 h post-injection.
99m Tc-RGD-βAla-(Arg 11 ) CCMSH exhibited the highest tumor to kidney uptake ratios among the 99m Tc-labeled hybrid peptides at 0.5, 2, 4, and 24 h post-injection. Two B16/F1 melanoma-bearing C57 mice were injected with 99m Tc-RGD-βAla-(Arg 11 ) CCMSH or 99m Tc-RGD-Ahx-(Arg 11 )CCMSH through the tail vein to visualize the tumors 2 h after dose administration. The representative whole-body SPECT/CT images The effects of l-lysine co-injection on the renal and tumor uptake of )CCMSH were calculated based on the results published in the references (Yang et al. 2009 (Yang et al. , 2010b 
Discussion
High mortality of malignant melanoma is associated with the occurrence of aggressive metastases. Novel and effective treatments are urgently needed to fulfill the desperate need for melanoma treatment since no curative treatment exists for metastatic melanoma. Recently, we have utilized the MC1 receptor-targeting (Arg 11 )CCMSH peptide as a delivery vehicle to transport the RGD motif into melanoma cells to induce apoptosis (Yang et al. 2009 (Yang et al. , 2010b Tc-RGD-Arg-(Arg 11 )CCMSH to their non-specific renal uptake through l-lysine co-injection in our previous work (Yang et al. 2009 (Yang et al. , 2010b . Hence, we designed two new α-MSH hybrid peptides with less overall positive charges to examine whether the reduction of the overall positive charge of the 99m Tc-labeled α-MSH hybrid peptides could further reduce their renal uptake in this study. Specifically, we substituted the positively-charged Lys or Arg linker with the neutral βAla or Ahx linker to generate RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH. The replacement of the positively-charged Lys or Arg linker with the neutral βAla or Ahx linker did maintain the )CCMSH were cited from the references (Yang et al. 2009 (Yang et al. , 2010b low nanomolar MC1 receptor-binding affinities of RGDβAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH. RGD-βAla-(Arg 11 )CCMSH displayed comparable IC 50 value as RGD-Arg-(Arg 11 )CCMSH (0.8 vs. 0.7 nM), whereas RGD-Ahx-(Arg 11 )CCMSH showed similar IC 50 value as RGD-Lys-(Arg 11 )CCMSH (1.3 vs. 2.1 nM). The difference in receptor-binding affinity between the RGDβAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH was attributed to the length of the hydrocarbon between the βAla linker and Ahx linker. The βAla linker has 2 hydrocarbons, whereas the Ahx linker has 5 hydrocarbons. The IC 50 value of RGD-βAla-(Arg 11 )CCMSH was lower than that of RGD-Ahx-(Arg 11 )CCMSH, indicating that the shorter hydrocarbon linker makes the RGD-βAla-(Arg 11 ) CCMSH peptide better fit in the receptor-binding pocket for enhanced receptor-binding affinity in vitro. The length of the hydrocarbon linker also displayed a profound impact on the receptor-binding affinities of DOTA-conjugated bombesin peptides (Garrison et al. 2008; Hoffman et al. 2003) . The hydrocarbon linkers ranging from 5-carbon to 8-carbon between the DOTA and bombesin peptide resulted in 0.6-1.7 nM receptor-binding affinities for bombesin peptides (Garrison et al. 2008) . Either shorter or longer hydrocarbon linkers dramatically reduce the receptor-binding affinity by 100-fold. The difference in linker length between the α-MSH and bombesin peptides demonstrated that it is necessary to carefully investigate which linker is suitable for optimal tumor uptake when switching from one type of peptide to another type of peptide.
It is worthwhile to note that the (Arg 11 )CCMSH moiety serves as a site-specific chelating system for direct labe- Tc-RGD-Lys-(Arg 11 )CCMSH in our previous report (Yang et al. 2009 (Yang et al. , 2010b . Specifically, 99m Tc-RGDArg-(Arg 11 )CCMSH displayed 44 % higher tumor uptake and 33 % less renal uptake than 99m Tc-RGD-Lys-(Arg 11 ) CCMSH at 2 h post-injection (Yang et al. 2009 (Yang et al. , 2010b Tc-RGD-Ahx-(Arg 11 )CCMSH enhanced the tumor to kidney uptake ratios. The tumor to kidney uptake ratio of 99m Tc-RGD-Ahx-(Arg 11 )CCMSH was 1.1, 1.4, 1.2, and 1.8 times the tumor to kidney uptake ratio of 99m Tc-RGD-Arg-(Arg 11 )CCMSH at 0.5, 2, 4, and 24 h post-injection, respectively. Among these four 99m Tclabeled RGD-conjugated α-MSH hybrid peptides (Fig. 3) , 99m Tc-RGD-βAla-(Arg 11 )CCMSH exhibited the highest tumor to kidney uptake ratios. The tumor to kidney uptake ratio of 99m Tc-RGD-βAla-(Arg 11 )CCMSH was 1.5, 1.9, 2.4, and 2.3 times the tumor to kidney uptake ratio of Tc-RGD-Ahx-(Arg 11 )CCMSH. Non-specific renal uptake of peptides is mainly caused by glomerular filtration and tubular reabsorption (Maack et al. 1979; Mørgenson et al. 1977; Silbernagl et al. 1988) because peptides are generally filtered in the glomerulus and reabsorbed in the cells of the proximal tubule. Positively-charged peptides can bind to the negatively-charged tubule cells through electrostatic interaction. Thus, positively-charged amino acids such as l-lysine and l-arginine could be used to decrease the renal uptake of radiolabeled peptides by shielding such electrostatic interaction (Béhé et al. 2005; Behr et al. 1995 Behr et al. , 1996 . Over the past several years, both colchicine and megalin were reported to be involved in the renal uptake of 111 In-DTPA-Octreotide (Christensen et al. 1998; De Jong et al. 2005; Rolleman et al. 2004 ). The use of colchicine prevented endocytosis in tubular cells, thus decreased the renal uptake up to 25 % in a rat model (Rolleman et al. 2004) . Recently, more research efforts have focused on decreasing the renal reabsorption of radiolabeled peptides through interfering with endocytic receptors on the proximal tubular cells. Specifically, megalin is a multiligand receptor which has four cycteinerich ligand-binding domains. Thus, various structurally different peptides and proteins (i.e., albumin and vitamin D-binding protein) can bind to megalin. For instance, albumin-derived peptides efficiently decreased the renal uptake of radiolabeled peptides by 26-88 % (Vegt et al. 2012) . Although the mechanism has not been completely identified, interestingly, it was reported that charges may play an important role in megalin-ligand binding (Birn et al. 2006; Gotthardt et al. 2007; Orlando et al. 1997) . In this study, we managed to reduce the renal uptake through structural modification of the peptides. Tc-RGD-Ahx-(Arg 11 )CCMSH is related to the endocytic receptors on the proximal tubular cells.
Both RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 ) CCMSH exhibited remarkable cytotoxicity in B16/F1 melanoma cells. Single treatment with 0.1 µM of RGD-βAla-(Arg 11 )CCMSH or RGD-Ahx-(Arg 11 )CCMSH decreased the survival percentage by 71 and 67 %, respectively. The treatment with 0.1 µM of RGD peptide did not reduce the survival percentage of B16/F1 cells significantly (p > 0.05), indicating that the internalization of RGD-βAla-(Arg 11 ) CCMSH and RGD-Ahx-(Arg 11 )CCMSH played a key role in their cytotoxicity. Although the treatment of 0.1 µM of (Arg 11 )CCMSH peptide reduced the survival percentage of B16/F1 cells by 15 % (p < 0.05), the reduction in survival percentage of RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH was 4.8 and 4.5 times the reduction in survival percentage of (Arg 11 )CCMSH. Dramatic difference in cytotoxicity between RGD-βAla-(Arg 11 )CCMSH/RGDAhx-(Arg 11 )CCMSH and (Arg 11 )CCMSH demonstrated that the cytotoxic effects of RGD-βAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH hybrid peptides were due to the apoptotic effect of the RGD motif in the hybrid peptide. The cytotoxic effects generated by the treatments of RGDβAla-(Arg 11 )CCMSH and RGD-Ahx-(Arg 11 )CCMSH highlighted the potential of treating the melanoma with the targeted radiation and apoptosis inducer. High-energy beta-emitter 188 Re is a therapeutic radionuclide and shares similar coordination chemistry with 99m Tc. Thus, the RGDconjugated hybrid peptide could be directly labeled with 188 Re for melanoma treatment without peptide structural modification. Tc-RGD-βAla-(Arg 11 )CCMSH showed more favorable pharmacokinetic properties than 99m Tc-RGD-Ahx-(Arg 11 )CCMSH in this study. The enhanced tumor to kidney uptake ratio of 99m Tc-RGD-βAla-(Arg 11 ) CCMSH would facilitate the potential application of 188 Re-RGD-βAla-(Arg 11 )CCMSH for melanoma treatment in the future.
Conclusions
The replacement of the positively-charged Arg linker with the neutral βAla or Ahx linker dramatically decreased the non-specific renal uptake of 99m Tc-RGD-βAla-(Arg 11 ) CCMSH and 99m Tc-RGD-Ahx-(Arg 11 )CCMSH by 62 and 61 % at 2 h post-injection. )CCMSH as a novel MC1 receptor-targeting therapeutic peptide for melanoma treatment in the future.
